Literature DB >> 19878059

Human embryonic stem cell-derived mesenchymal stromal cell transplantation in a rat hind limb injury model.

Juha P Laurila1, Lilja Laatikainen, Maria D Castellone, Parul Trivedi, Jari Heikkila, Ari Hinkkanen, Peiman Hematti, Mikko O Laukkanen.   

Abstract

BACKGROUND AIMS: Mesenchymal stromal cells (MSC) have been used in a wide variety of pre-clinical experiments and in an increasing number of human clinical trials. Although many of these studies have shown different levels of engraftment, the exact fate of MSC after transplantation and the tissue response to their engraftment have not been investigated in detail. In the present work we studied the distribution of human MSC in a rat hind limb ischemic injury model immediately after transplantation and also analyzed the recipient tissue response to transplanted cells.
METHODS: We tracked the in vivo fate of the transplanted MSC utilizing bioluminescence imaging, fluorescence microscopy and gene/protein expression analysis in a rat hind limb ischemia model. We also monitored the viability of transplanted cells by graft versus recipient expression analysis and determined the angiogenic and proliferative effect of transplantation by histologic staining.
RESULTS: According to imaging analysis only a small portion of cells persisted for an extended period of time at the site of injury. Interestingly, recipient versus graft expression studies showed increased synthesis of rat-origin angiogenic factors and no human-origin mRNA or protein synthesis in transplanted tissues. More importantly, despite the lack of robust engraftment or growth factor secretion the transplantation procedure exerted a significant pro-angiogenic and pro-proliferative effect, which was mediated by angiogenic and mitogenic signaling pathways.
CONCLUSIONS: Our results show an immediate temporal tissue effect in response to MSC transplantation that may represent a novel indirect paracrine mechanism for the beneficial effects of cell transplantation observed in injured tissues.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19878059      PMCID: PMC2889035          DOI: 10.3109/14653240903067299

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  42 in total

Review 1.  Mesenchymal stem cells: paradoxes of passaging.

Authors:  Elisabeth H Javazon; Kirstin J Beggs; Alan W Flake
Journal:  Exp Hematol       Date:  2004-05       Impact factor: 3.084

Review 2.  The therapeutic potential of mesenchymal stem cells. Cell- & tissue-based therapy.

Authors:  Sonia C Picinich; Pravin J Mishra; Prasun J Mishra; John Glod; Debabrata Banerjee
Journal:  Expert Opin Biol Ther       Date:  2007-07       Impact factor: 4.388

3.  In vivo commitment and functional tissue regeneration using human embryonic stem cell-derived mesenchymal cells.

Authors:  Nathaniel S Hwang; Shyni Varghese; H Janice Lee; Zijun Zhang; Zhaohui Ye; Jongwoo Bae; Linzhao Cheng; Jennifer Elisseeff
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-18       Impact factor: 11.205

4.  Mesenchymal stem cells regulate angiogenesis according to their mechanical environment.

Authors:  Grit Kasper; Niels Dankert; Jens Tuischer; Moritz Hoeft; Timo Gaber; Juliane D Glaeser; Desiree Zander; Miriam Tschirschmann; Mark Thompson; Georg Matziolis; Georg N Duda
Journal:  Stem Cells       Date:  2007-01-11       Impact factor: 6.277

5.  Role of gp91phox (Nox2)-containing NAD(P)H oxidase in angiogenesis in response to hindlimb ischemia.

Authors:  Taiki Tojo; Masuko Ushio-Fukai; Minako Yamaoka-Tojo; Satoshi Ikeda; Nikolay Patrushev; R Wayne Alexander
Journal:  Circulation       Date:  2005-05-02       Impact factor: 29.690

6.  Survival of human mesenchymal stromal cells from bone marrow and adipose tissue after xenogenic transplantation in immunocompetent mice.

Authors:  P Niemeyer; J Vohrer; H Schmal; P Kasten; J Fellenberg; N P Suedkamp; A T Mehlhorn
Journal:  Cytotherapy       Date:  2008       Impact factor: 5.414

7.  Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin.

Authors:  G D'Angelo; I Struman; J Martial; R I Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

8.  Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells.

Authors:  Ivana Rosová; Mo Dao; Ben Capoccia; Daniel Link; Jan A Nolta
Journal:  Stem Cells       Date:  2008-05-29       Impact factor: 6.277

Review 9.  Role of mesenchymal stromal cells in solid organ transplantation.

Authors:  Peiman Hematti
Journal:  Transplant Rev (Orlando)       Date:  2008-07-24       Impact factor: 3.943

Review 10.  The chemokine system in arteriogenesis and hind limb ischemia.

Authors:  Paula K Shireman
Journal:  J Vasc Surg       Date:  2007-06       Impact factor: 4.268

View more
  28 in total

Review 1.  Potential of human embryonic stem cells in cartilage tissue engineering and regenerative medicine.

Authors:  Wei Seong Toh; Eng Hin Lee; Tong Cao
Journal:  Stem Cell Rev Rep       Date:  2011-09       Impact factor: 5.739

2.  Characterization and in vivo testing of mesenchymal stem cells derived from human embryonic stem cells.

Authors:  William Gruenloh; Amal Kambal; Claus Sondergaard; Jeannine McGee; Catherine Nacey; Stefanos Kalomoiris; Karen Pepper; Scott Olson; Fernando Fierro; Jan A Nolta
Journal:  Tissue Eng Part A       Date:  2011-03-04       Impact factor: 3.845

Review 3.  Do mesenchymal stem cells function across species barriers? Relevance for xenotransplantation.

Authors:  Jiang Li; Mohamed B Ezzelarab; David K C Cooper
Journal:  Xenotransplantation       Date:  2012 Sep-Oct       Impact factor: 3.907

Review 4.  Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells.

Authors:  Candice Ashmore-Harris; Madeleine Iafrate; Adeel Saleem; Gilbert O Fruhwirth
Journal:  Mol Ther       Date:  2020-03-20       Impact factor: 11.454

5.  Enhanced therapeutic neovascularization by CD31-expressing cells and embryonic stem cell-derived endothelial cells engineered with chitosan hydrogel containing VEGF-releasing microtubes.

Authors:  Sangho Lee; Chandra M Valmikinathan; Jaemin Byun; Sangsung Kim; Geehee Lee; Nassir Mokarram; S Balakrishna Pai; Elisa Um; Ravi V Bellamkonda; Young-sup Yoon
Journal:  Biomaterials       Date:  2015-06-11       Impact factor: 12.479

6.  Local delivery of allogeneic bone marrow and adipose tissue-derived mesenchymal stromal cells for cutaneous wound healing in a porcine model.

Authors:  Summer E Hanson; Kyle R Kleinbeck; David Cantu; Jaeyhup Kim; Michael L Bentz; Lee D Faucher; W John Kao; Peiman Hematti
Journal:  J Tissue Eng Regen Med       Date:  2013-02-18       Impact factor: 3.963

Review 7.  Clinical applications of mesenchymal stem cells in soft tissue augmentation.

Authors:  Summer E Hanson; Karol A Gutowski; Peiman Hematti
Journal:  Aesthet Surg J       Date:  2010 Nov-Dec       Impact factor: 4.283

8.  The effect of mesenchymal stromal cell-hyaluronic acid hydrogel constructs on immunophenotype of macrophages.

Authors:  Summer E Hanson; Suzanne N King; Jaehyup Kim; Xia Chen; Susan L Thibeault; Peiman Hematti
Journal:  Tissue Eng Part A       Date:  2011-06-24       Impact factor: 3.845

Review 9.  Clinical applications of mesenchymal stem cells in laryngotracheal reconstruction.

Authors:  Summer Hanson; Susan L Thibeault; Peiman Hematti
Journal:  Curr Stem Cell Res Ther       Date:  2010-09       Impact factor: 3.828

Review 10.  Mesenchymal stem cells as a treatment for peripheral arterial disease: current status and potential impact of type II diabetes on their therapeutic efficacy.

Authors:  Jinglian Yan; Guodong Tie; Ting Yu Xu; Katharine Cecchini; Louis M Messina
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.